Media Pack
News

Current Edition

JCS Volume 15 Issue 3
 
Regional News

Novartis aims to keep canakinumab’s early lung cancer hopes alive despite metastatic failure

When Novartis failed in an attempt to repurpose Ilaris for metastatic non-small cell lung cancer (NSCLC), the Swiss pharma played up signs that it said supported cont...
13 April 2022 Regional News cancer | cell
Continue Reading →
Regional News

In major shake-up, Novartis combines pharma, oncology units, leaving cancer commercial head, CMO out of job

Novartis CEO Vas Narasimhan is giving the Swiss pharma a huge makeover even ahead of a possible spinoff of generics unit Sandoz, pushing out three C-level executives ...
4 April 2022 Regional News cancer | makeover
Continue Reading →
Regional News

Novo Nordisk and Novartis put Victoza patent suit to bed, teeing up Sandoz copycat by 2024

After Teva Pharmaceutical snagged the OK to launch its Victoza generic in 2023, another copycat has secured a launch timeline for its generic to Novo Nordisk’s aging ...
23 March 2022 Regional News copycat | Novartis
Continue Reading →
Regional News

As Russian invasion persists, Roche, Teva, Novartis, Merck and more make renewed push to support besieged Ukraine

As Ukraine holds the line against the Russian invasion, pharma majors are making a renewed push to adjust operations in the region and supply the besieged country wit...
23 March 2022 Regional News Merck | Novartis
Continue Reading →
Regional News

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war

Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are among...
17 March 2022 Regional News AbbVie | Eli Lilly
Continue Reading →
Regional News

Novartis’ Sandoz reportedly the target of $25B buyout bid from Carlyle and Blackstone

As Novartis reviews its generics business, the list of potential Sandoz suitors has grown. The deal could become one of the biggest generic industry acquisitions ever...
2 February 2022 Regional News Blackstone | Bloomberg
Continue Reading →
Regional News

Novartis, Amgen settle their dueling lawsuits over migraine drug Aimovig

Novartis and Amgen have spent years arm wrestling one another over their development and commercialization deal on migraine prevention drug Aimovig. Now, the parties ...
2 February 2022 Regional News Amgen | drug
Continue Reading →
Regional News

ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T meds

Kymriah’s shocking failure in earlier lymphoma treatment has raised doubts about the Novartis drug’s potency in light of impressive victories from rival CAR-Ts by Gil...
15 December 2021 Regional News ASH 2021 | Breyanzi
Continue Reading →
Regional News

For pharmas dealing with HCPs, the future is digital first—and sales reps 2nd

While many people are suffering from Zoom fatigue and looking forward to in-person meetups, that isn’t really the case when it comes to HCPs and pharma reps. As with...
13 December 2021 Regional News Amgen | Bristol Myers Squibb
Continue Reading →
Regional News

Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz

Amid Novartis' strategic review of generics unit Sandoz, last month came word that Swedish investment group EQT and the Struengmann brothers of Germany were consideri...
13 December 2021 Regional News divestment | generics
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte